BioRestorative Therapies (NASDAQ:BRTX) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

BioRestorative Therapies (NASDAQ:BRTX) posted its quarterly earnings results on Tuesday. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.06, Yahoo Finance reports. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative return on equity of 96.09% and a negative net margin of 7,303.33%. During the same quarter last year, the business earned ($0.77) earnings per share.

BioRestorative Therapies Price Performance

Shares of BioRestorative Therapies stock traded up $0.00 on Wednesday, hitting $1.41. 17,688 shares of the company’s stock traded hands, compared to its average volume of 1,077,670. The firm’s 50-day moving average price is $1.68 and its two-hundred day moving average price is $1.50. The stock has a market capitalization of $9.56 million, a PE ratio of -0.61 and a beta of 63.47. BioRestorative Therapies has a one year low of $1.03 and a one year high of $3.67.

Analyst Ratings Changes

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $15.00 target price on shares of BioRestorative Therapies in a research note on Wednesday, June 12th.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.